Previous close | 10.16 |
Open | N/A |
Bid | 23.35 |
Ask | 26.00 |
Strike | 140.00 |
Expiry date | 2024-08-02 |
Day's range | 10.16 - 10.16 |
Contract range | N/A |
Volume | |
Open interest | 9 |
CureVac is also eligible for future royalties. CureVac shares jumped 12% in early trading Wednesday, while GSK’s American depositary receipt slipped 0.2%. Shares of Moderna a leading mRNA vaccine manufacturer, were up 0.9%.
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.
Moderna stock tumbled in late June after unveiling updated test results for its RSV vaccine. Is MRNA stock now a sell?